Has Elshami Elamin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $17,368 in general payments to Elshami Elamin, MD across 996 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Elshami Elamin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Elshami Elamin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Elshami Elamin, MD

Medical Oncology · Newton, KSNPI 1841254521

Payments from drug & device makers

$17,368in general payments, 2019–2025

Across 996 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$1K
Pfizer$1K
AstraZeneca$1K
E.r. Squibb & Sons, L.L.C.$891
Merck$737
Johnson & Johnson$690
plus $11K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	72	$1,129
Pfizer	86	$1,083
AstraZeneca(2 entities)	49	$1,025
E.r. Squibb & Sons, L.L.C.	68	$891
Merck	43	$737
Johnson & Johnson	45	$690
GSK	36	$664
Bristol Myers Squibb	40	$653
Genentech USA, Inc.	39	$635
Amgen	37	$622
Gilead(2 entities)	35	$573
AbbVie	29	$532
Astellas Pharma US Inc	20	$510
Lilly USA, LLC	19	$491
Sanofi	22	$485
Seagen Inc.	27	$455
Array Biopharma Inc	27	$367
Takeda Pharmaceuticals U.S.A., Inc.	17	$337
Daiichi Sankyo Inc.	17	$319
Exelixis Inc.	15	$305
Incyte Corporation	17	$282
Regeneron Healthcare Solutions, Inc.	11	$276
Tersera Therapeutics LLC	10	$274
Bayer	11	$190
Sobi, Inc	8	$185
Boehringer Ingelheim	7	$172
Eisai Inc.	9	$162
Ipsen Biopharmaceuticals, Inc	8	$156
Apellis Pharmaceuticals, Inc.	7	$150
Genmab U.S., Inc.	6	$149
Dendreon Pharmaceuticals LLC	6	$144
Karyopharm Therapeutics Inc.	7	$139
Agios Pharmaceuticals, Inc.	7	$132
Stemline Therapeutics Inc.	8	$128
G1 Therapeutics, Inc.	7	$126
Pharmacyclics LLC, An Abbvie Company	6	$120
Rigel Pharmaceuticals, Inc.	7	$113
Clovis Oncology, Inc.	8	$108
Puma Biotechnology, Inc.	6	$102
Spectrum Pharmaceuticals Inc.	6	$102
EMD Serono, Inc.	6	$98
Emmaus Medical, Inc.	4	$94
Adaptive Biotechnologies Corporation	5	$93
Jazz Pharmaceuticals Inc.	4	$93
Beigene USA, Inc.	6	$91
Foundation Medicine, Inc.	5	$88
Kyowa Kirin, Inc.	5	$83
Sumitomo Pharma America, Inc.	4	$79
Pharmacosmos Therapeutics Inc.	4	$68
Mylan Institutional Inc.	3	$57
Organon	3	$46
Iovance Biotherapeutics, Inc.	2	$46
Taiho Oncology, Inc.	2	$35
Sun Pharmaceutical Industries Inc.	2	$31
Beone Medicines USA, Inc.	1	$31
CTI Biopharma Corp.	2	$30
Deciphera Pharmaceuticals Inc.	1	$28
Caris MPI, Inc.	2	$28
Coherus Oncology, Inc.	1	$28
Blueprint Medicines Corporation	2	$27

How this compares

$17,368 in reported general payments places this provider in the 30th percentile of 25 medical oncology providers in Kansas.

See all medical oncology providers in Kansas →

Medicare billing

Part B allowed, 2024

$3,333,325

Medicare patients

652

Services billed

139,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Newton

Gregory NanneyNewton$7K
Weijing SunWestwood$5.1M
Rahul ParikhWestwood$4.5M
Anwaar SaeedWestwood$4.1M
Ajjai AlvaOverland Park$3.7M
Joaquina BarandaWestwood$2.7M
Anne OdeaWestwood$2.2M
Nisreen HaideriOverland Park$1.2M
Benjamin GeorgeColby$1.1M
Stephen WilliamsonWestwood$861K

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →